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Abstract
The EGFR adaptor protein, CIN85, has been shown
to promote breast cancer malignancy and hypoxia-
inducible factor (HIF) stability. However, the mechan-
isms underlying cancer promotion remain ill deﬁned.
Here we show that CIN85 is a novel binding partner of
the main HIF-prolyl hydroxylase, PHD2, but not of
PHD1 or PHD3. Mechanistically, the N-terminal SRC
homology 3 domains of CIN85 interacted with the
proline-arginine–rich region within the N-terminus of
PHD2, thereby inhibiting PHD2 activity and HIF deg-
radation. This activity is essential in vivo, as speciﬁc
loss of the CIN85–PHD2 interaction in CRISPR/Cas9-
edited cells affected growth and migration properties,
as well as tumor growth in mice. Overall, we discovered
a previously unrecognized tumor growth checkpoint
that is regulated by CIN85-PHD2 and uncovered an
essential survival function in tumor cells by linking
growth factor adaptors with hypoxia signaling.
Signiﬁcance: This study provides unprecedented evi-
dence for an oxygen-independent mechanism of PHD2
regulation that has important implications in cancer cell
survival.
Graphical Abstract: http://cancerres.aacrjournals.org/
content/canres/79/16/4042/F1.large.jpg.
Introduction
Hypoxia-inducible factors (HIF) are crucial in the adaption
of tumor cells to the reduced availability of oxygen (1). From
the HIFs known today, HIF1a and HIF2a appear to be essential
promotors of malignant transformation, cell proliferation,
invasion, and motility (2). Although several mechanisms con-
tribute to the regulation of HIFa expression (3), regulation
of HIF stability by the family of HIF-prolyl hydroxylases
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(PHD) is reported to be of major importance. Under normoxic
conditions, PHDs hydroxylate proline residues in HIF1a and
HIF2a (4). This allows further recruitment of an E3-ubiquitin
ligase complex containing the von-Hippel Lindau protein
(VHL; ref. 5), which results in the proteasomal degradation
of HIF1a and HIF2a.
The prooncogenic adaptor protein, CIN85, is a multi-modular
scaffold protein, able of mediating various molecular interac-
tions. Apart from being involved in downregulation of receptor
tyrosine kinases such as EGFR (6), ErbB2/Her2 (7), and hepato-
cyte growth factor receptor (MET; ref. 8), CIN85 also affects
apoptosis, adhesion (9), and invasion (10). Earlier ﬁndings,
including our own, showed that CIN85 promotes development
of various cancers including breast cancer and displays highest
levels in the most hypoxic areas of tumor tissues, which also
usually display high HIFa levels (11, 12). In addition, we could
previously show that CIN85 appears to induce HIF1a stability via
a so far unknown mechanism (13).
Thus, we hypothesized that CIN85may affect HIFa stability by
affecting the HIF-PHDs. Accordingly, we examined the potential
involvement of PHDs in CIN85-mediated HIFa stability in a
more mechanistic manner. Our current study shows that CIN85
is a novel binding partner of themainHIF-hydroxylase PHD2.We
further deﬁned that the three SRC homology 3 (SH3) domains of
CIN85 and the proline-arginine (PR)-rich area within the amino
acids 77–100 in theN-terminus of PHD2 are ofmajor importance
for theCIN85–PHD2 complex formation. In addition,weutilized
a CRISPR/Cas9-mediated EGLN1 (PHD2) gene editing approach
to unravel the impact of the CIN85–PHD2 interaction on HIFa
stability and cellular behavior in triple-negative breast cancer cells,
that is, cells that do not express estrogen receptor, progesterone
receptor, and HER2/neu and therefore model the malignant
breast cancer growth. The abrogation of PHD2–CIN85 complex
formation in the CRISPR/Cas9-edited cells resulted in higher
PHD2 activity and subsequently lower HIF1a and HIF2a levels,
as well as in a less malignant cellular phenotype. Together, we
show that CIN85 acts as a novel binding partner of PHD2, which
can prevent prolyl-hydroxylation and degradation of HIFa sub-
units, thereby promoting HIFa stability and breast cancer
malignancy.
Materials and Methods
Chemicals
All biochemicals and enzymes were of analytic grade and were
purchased from commercial suppliers. EGF was from Sigma-
Aldrich, restriction enzymes were from Thermo Fisher Scientiﬁc,
and FG-4592 was from Cayman Chemical.
Cell culture
Human embryonic kidney 293 (HEK-293, # CRL-1573),
human breast carcinoma cell lines [MDA-MB-231 (#HTB-26),
Hs578T (#HTB-126), and BT-549 (#HTB-122)] were authenticat-
ed andpurchased fromATCC.All cell lineswere testedMycoplasma
negative by using the MycoAlert Detection Kit (Lonza). In all
experiments the number of cell passages usedwas below10.HEK-
293, MDA-MB-231, and Hs578TH were maintained in DMEM
supplemented with 10% FCS, 2 mmol/L L-glutamine, 50 IU/mL
penicillin, and 50 mg/mL streptomycin in a humidiﬁed atmo-
sphere containing 5%CO2, 16%O2, and 79%N2 at 37C. The cell
line, BT-549, was maintained in RPMI1640 medium. When
indicated, the cells were incubated under hypoxic conditions in
a Ruskinn Sci-Tive-N hypoxia workstation under 5% or 1% O2,
5% CO2 balanced with N2 for 6 hours.
Plasmids and site-directed mutagenesis
pClneo-Myc-CIN85 D111G was a gift from Yutaka Hata
(Addgene plasmid catalog no. 47935), the D114G mutation was
eliminated by site-directed mutagenesis (QuikChange Mutagen-
esis Kit, Promega). The constructs for thebimolecularﬂuorescence
complementation assay (BiFC) were generated by PCR, the
respective PCR products were subcloned into the BamHI and
XbaI sites (for PHD2) or EcoRI and XbaI sites (for CIN85) of
pcDNA3-YN [nonﬂuorescent N-terminus of yellow-ﬂuorescent
protein (YFP)] or pcDNA3-YC (nonﬂuorescent C-terminus of
YFP) plasmids, respectively (14). The constructs encoding CIN85
deletion variants and the ones allowing the expression of the
recombinant GST-SH3A, GST-SH3B, GST-SH3C, GST-Pro, GST-
Ser, and GST-CC fusion proteins were described previously (15).
The expression vectors for PHD2, PHD1, and PHD3 were
described previously (16) and further details are included as
Supplementary Information.
Protein preparation and Western blotting
The cells were lysed in lysis buffer [50 mmol/L Gris-HCl, pH
7.5, 150 mmol/L NaCl, 1% Triton X-100, 1 mmol/L o-vanadate,
50 mmol/L NaF, 2 mmol/L +DTA, 1 mmol/L PMSF, complete
protease inhibitor cocktail tablet (Roche)], kept on ice for 10
minutes and centrifuged at 14,000 g for 20 minutes at 4C. For
EGF stimulation, cells were cultured in starvation medium
(DMEM containing 0.1% FBS) for 24 hours, then treated with
EGF (100 ng/mL), and lysed as described above. The levels of
HIF1a, HIF2a, PHD1, PHD2, PHD3, Myc-CIN85, V5-PHD1,
V5-PHD2, V5-PHD3, Flag-CIN85, CIN85, phospho-AKT, and
phospho-ERK1/2 were detected by Western blotting from
whole-cell extracts. Proteins (20–100 mg per sample) were sepa-
rated by electrophoresis on 7.5%–12% polyacrylamide gels and
transferred to nitrocellulose membranes. The membranes were
incubated with the following antibodies: HIF1a (catalog no.
610959, BD Biosciences), HIF2a (catalog no. NB100-122, Novus
Biologicals), PHD1 (NB100-310, Novus Biologicals), PHD2
(catalog no. 3293, Cell Signaling Technology), PHD3 (NB100-
139, Novus Biologicals), Myc-Tag (catalog no. 2278, Cell Signal-
ing Technology), V5-Tag (catalog no. R96025, Thermo Fisher
Scientiﬁc), Flag M2 (catalog no. F1804, Sigma-Aldrich,), CIN85
(catalog no. 12304, Cell Signaling Technology), phospho-AKT
(pSer473) (catalog no. 9271, Cell Signaling Technology), AKT
(catalog no. 9272, Cell Signaling Technology), phospho-ERK1/2
(pThr202/ pTyr204) (catalog no. 9101, Cell Signaling Technol-
ogy), ERK1/2 (catalog no. 9107, Cell Signaling Technology),
a-tubulin (B-5-1-2) (catalog no. T5168, Sigma-Aldrich), CD2AP
(catalog no. 25272, Santa Cruz Biotechnology), and b-actin
(A5316, Sigma-Aldrich) overnight at 4C. Appropriate secondary
antibodies (peroxidase-conjugated IgG, Bio-Rad) were used. The
ECL Kit (GE Healthcare) was used for signal detection. Blots were
quantiﬁed by densitometry with the Image Quant TL Program
(GEHealthcare); densitometry datawere normalized toa-tubulin
or b-actin.
Immunoprecipitation
For the coimmunoprecipitation of CIN85 and PHDs, HEK-293
cells were transiently transfected with expression plasmids
CIN85 Inhibits the Function of PHD2
www.aacrjournals.org Cancer Res; 79(16) August 15, 2019 4043
on October 25, 2019. © 2019 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Published OnlineFirst May 29, 2019; DOI: 10.1158/0008-5472.CAN-18-3852 
encodingMyc-taggedCIN85 andV5-tagged PHDs (PHD1, PHD2,
and PHD3) or Flag-tagged CIN85 lacking either SH3A, SH3B,
SH3C, or all three SH3 domains, and V5-tagged PHD2. Immu-
noprecipitations were carried out as described previously (3).
Cellswere harvested 48hours posttransfection,washed twicewith
ice-cold PBS, and lysed as described above. Aliquots of cleared
HEK-293 cell lysates containing 1 mg of total protein were mixed
with protein G Sepharose beads (GE Healthcare) andMyc-tagged
CIN85 was immunoprecipitated with the Myc-tag antibody; the
Flag-tagged CIN85 variants were immunoprecipitated with the
Flag M2 antibody at 4C overnight. For the coimmunoprecipita-
tion of CIN85 and PHD2 at the endogenous level, CIN85 was
immunoprecipitated from the lysates of MDA-MB-231, Hs 578T,
and BT-549 cells with the SH3A-CIN85 mAb (17) or CD2AP
(catalog no. 25272, Santa Cruz Biotechnology). The next day the
beads were washed 5 times with lysis buffer, the immune com-
plexes were then resolved by SDS-PAGE, and analyzed with
antibodies against the Myc and V5 epitope, or PHD2.
In vitro hydroxylation assay
The catalysts [PHD2 wild-type (wt), D52–98 PHD2, and PR
mut 2] in pcDNA vectors containing a T7 promoter were in vitro
transcribed and translated (IVTTed) in rabbit reticulocyte lysate by
using the TnT Quick Coupled Transcription/Translation System
(Promega) in the presence of [35S]Met. An aliquot of the
IVTTed catalysts was analyzed on a 10% SDS-page gel to ensure
equal expression levels. The rest of the IVTTed catalysts (45 mL)
wasused to in vitrohydroxylate [3H]Pro-labelledHIF1a-ODDDin
the presence of cofactors Fe2þ (5 mmol/L), 2-oxoglutarate
(320 mmol/L), and ascorbate (2mmol/L) at 37C for 30minutes.
The generation of [3H] 4-hydroxyproline was determined by a
radiochemical assay (for details see ref. 18).
Xenograft mouse model
A total of 5  105 cells of CRISPR/Cas9-generated MDA-MB-
231 cells expressing edited EGLN1 (PHD2) (E10 and E12)
together with scrambled (S) control cells were injected in
the thoracic and inguinal mammary fat pad of 4-week-old
female athymic nude mice (Envigo). The mice were housed
in individually ventilated cages with water and food ad libitum
for up to 5 weeks. The animals were euthanized by CO2
inhalation and additional cervical dislocation, and the tumors
were collected. All animals were housed in the laboratory
Animal Center of the University of Oulu (Oulu, Finland) in
speciﬁc pathogen-free facilities on a 12-hour light/dark cycle, at
a constant temperature of 22C. The protocol for animal
use and experiments was approved by the National Animal
Experimental Board of Finland, as well as the Animal Welfare
Body of the Laboratory Animal Center and conducted accord-
ing to the EU directive 2010/63/EU. The volume of the tumors
formed was calculated as described previously (19).
Statistical analysis
The results are presented as mean values  SD of at least three
independent experiments. Statistical analyses were performed
using Student two-tailed t test. Differences of P  0.05 were
considered statistically signiﬁcant.
Supplementary material summary
Supplementary material consists of one table listing the
sequences of the oligonucleotides used in the study followed by
six supplementary ﬁgures containing the results of the GST-pull
downs between CIN85 and PHD2 fragments (Supplementary
Figs. S1 and S2), generation of E10 and E12 MDA-MB-231
cells lacking the CIN85–PHD2 interaction part of PHD2
(Supplementary Fig. S3), Western blot data and qRT-PCR
from CRISPR/Cas9-edited EGLN1 cells (Supplementary Figs. S5
and S6), proliferation and wound-healing assay data from
CRISPR/Cas9-edited EGLN1 cells in the presence of FG-4592,
overexpressed HIF1a, and PHD2 (Supplementary Fig. S7),
and analyses of the off-target effects in the CRISPR/Cas9-edited
EGLN1 cells (Supplementary Fig. S8). Plasmids and site-directed
mutagenesis, GST-pull down, ﬂuorescence microscopy, CRISPR/
Cas9-mediated EGLN1 gene editing, lentivirus-mediated expres-
sion of single guide RNAs (sgRNA) and Cas9, genomic DNA
extraction and genotyping, RNA extraction and qRT-PCR, scan-
ning electron microscopy, monolayer colony formation assay,
and live cell imaging assays surface plasmon resonance (SPR) are
listed in Supplementary Materials.
Results
CIN85 and PHD2 undergo a direct interaction
We hypothesized that CIN85 contributes to HIF1a stabili-
zation by interfering with the function of PHDs via a direct
interaction and explored this in more detail. Because PHD2 is
the major variant regulating HIF1a levels (20), we ﬁrst per-
formed coimmunoprecipitation studies in the three triple-
negative breast cancer cell lines MDA-MB-231, BT-549, and Hs
578T. The results show that endogenous CIN85 and PHD2
interact in all three cell lines (Fig. 1A). Next, we investigated
whether CIN85 is also able to interact with PHD1 and PHD3,
which in contrast to PHD2 do not possess an N-terminal
MYND (myeloid, Nervy, and DEAF-1) zinc-ﬁnger domain. To
determine this, we performed coimmunoprecipitation studies
in HEK-293 cells transiently overexpressing V5-tagged PHD1,
PHD2, and PHD3 together with Myc-tagged CIN85. The coim-
munoprecipitation assays revealed that only PHD2 binds to
CIN85; no interaction of CIN85 with PHD1 or PHD3 could be
detected (Fig. 1B). Thus, these data indicate that CIN85 may
interfere with HIFa degradation only via PHD2 and not via
PHD1 or PHD3.
We next localized the PHD2–CIN85 complex in living cells by
performing a BiFC. The BiFC assay is based on the formation of a
ﬂuorescent complex when two proteins, fused to the noninter-
acting and nonﬂuorescent parts of, in our case, the N-terminal
and C-terminal halves of YFP, interact with each other (14).
Upon that interaction, the YFP ﬂuorescent complex is reconsti-
tuted and can be visualized. For this purpose, coding sequences of
CIN85 and PHD2 were subcloned into pcDNA3-CMV-YN and
pcDNA3-CMV-YC constructs, allowing the expression of PHD2
and CIN85 fused to the N-terminal or the C-terminal nonﬂuo-
rescent parts of YFP, respectively. A description of the constructs
used in the BiFC assay is schematically presented in Fig. 1C. BT-
549 cells were transfected with the CMV-CIN85-YN and CMV-
PHD2-YC constructs. Transfectionwith a combination of unfused
CMV-YN þ CMV-YC constructs served as a negative control,
whereas transfection with a construct, encoding full length YFP
served as a positive control. A punctated PHD2-CIN85BiFC signal
indicating the interaction of PHD2 with CIN85 could be mainly
visualized throughout the cytoplasm and to a lesser extent in the
nucleus of the transfected cells (Fig. 1D). Thus, these data indicate
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that PHD2 interacts with CIN85 predominantly in the cyto-
plasmic part of the cells.
To understand whether the interaction between PHD2 and
CIN85 is direct, we performed SPR experiments. To this end,
PHD2 was covalently immobilized to a SPR sensor chip, and a
concentration series of recombinant CIN85 was injected over
PHD2 and binding was assessed by SPR detection. The measure-
ments revealed that fulllength CIN85 bound to immobilized
PHD2 with an apparent Kd of 28.47  2.2 nmol/L (Fig. 1E and
F). Together, the data show that PHD2 and CIN85 interact in a
direct manner.
The three N-terminal SH3 domains of CIN85 bind to the
N-terminus of PHD2
Next, we investigated which parts of each protein are involved
in the interaction. CIN85 is a multi-domain adaptor protein
consisting of three SH3 domains (A, B, and C), a proline-rich
domain (Pro), and a serine-rich sequence (Ser), followed by a
coiled-coil (CC) domain. PHD2 harbors a ﬂexible N-terminus
with theMYND zinc-ﬁnger domain and a catalytic domain on the
C-terminus (Fig. 2A).
First, we performed GST-pull down experiments with recom-
binant GST-SH3A, GST-SH3B, GST-SH3C, GST-Pro, GST-Ser, and
Figure 1.
CIN85 interacts with PHD2.A, Endogenous PHD2was immunoprecipitated (IP) with CIN85 antibody fromMDA-MB-231, BT-549, and Hs 578T cells and probed
for PHD2 and CIN85. Blots from the input were probed with PHD1, -2, -3, CIN85, HIF1a, and HIF2a antibody. B,Western blot analysis of immunoprecipitates and
inputs from HEK-293 cells expressing V5-tagged PHD1, PHD2, or PHD3 and Myc-tagged CIN85. Blots from immunoprecipitates were probed with V5-tag
antibody; the input was probed with V5-tag, Myc-tag, and a-tubulin antibodies. C, Schematic presentation of BiFC assay constructs. The constructs CMV-CIN85-
YN and CMV-PHD2-YC allow expression of CIN85 and PHD2 as fusion proteins with the N-terminal or the C-terminal nonﬂuorescent parts of YFP (-YN and -YC)
under the control of the CMV promoter, respectively. Note that CMV-YN and CMV-YC protein parts are nonﬂuorescent and noninteracting; however, interacting
proteins such as CIN85 and PHD2 are able to reconstitute ﬂuorescent YFP. D, Visualization of the BiFC signal by confocal microscopy in BT-549 cells expressing
CMV-CIN85-YNþ CMV-PHD2-YC. No signal was detected upon expression of CMV-YNþ CMV-YC. Scale bar, 20 mm. E, The surface plasmon resonance
sensorgram of CIN85 binding to immobilized PHD2. Binding was assessed upon injection of a concentration series of CIN85 over immobilized PHD2. The CIN85
concentrations were 0, 10, 21, 42, 84, 168, 337, 675, 1,350, and 2,700 nmol/L (from bottom to top). F, The ﬁtted curve for different concentrations of CIN85
binding to immobilized PHD2 using the "Afﬁnity" model in the Biacore T200 evaluation software.
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GST-CC fusion proteins and lysates of HEK-293 cells transiently
expressing V5-PHD2 (Supplementary Fig. S1A). As a result, we
were able to identify that the SH3 domains from CIN85 are
responsible for the interaction with PHD2 (Supplementary
Fig. S1B), while no binding was observed between PHD2 and
other domains of CIN85.
We next tested whether the CIN85–PHD2 interaction will be
affected by the lack of a particular SH3 domain in CIN85. To do
that, coimmunoprecipitations with FLAG-tagged CIN85 and
mutants lacking either SH3A, SH3B, SH3C, or all three SH3
domains, as well as the CC domain together with V5-tagged
PHD2 were performed in HEK-293 cells (Fig. 2B). We found that
the CIN85–PHD2 interaction was present with full-length CIN85
or when CIN85 lacked either the SH3A, SH3B, SH3C, or CC
domain; however, absence of all three SH3domains abolished the
interaction (Fig. 2C).
The overall domain organization of CIN85 displays high
sequence and structural similarities to CD2-associated protein
Figure 2.
CIN85 interacts with the N-terminus of PHD2 via 3 SH3 domains.A, Schematic presentation of the CIN85 and PHD2 structure. CIN85 consists of three N-terminal
SH3 domains (A, B, and C), a proline-rich domain (Pro), and a serine-rich sequence (Ser), followed by a CC domain. The N-terminus of PHD2 possesses a MYND-
zinc-ﬁnger domain, while the catalytic domain of PHD2 is located in the C-terminus. B, Schematic presentation of FLAG-tagged CIN85 variants with a deletion of
either the SH3 A, SH3 B, SH3 C, or all three SH3 domains, as well as the CC domain used in the immunoprecipitation (IP) studies. C,Western blot analysis of
immunoprecipitates and inputs from HEK-293 cells expressing V5-tagged PHD2 variants and FLAG-tagged CIN85 variants. Blots from immunoprecipitates were
probed with V5-tag antibody, CD2AP, and CIN85 antibody; extracts were probed with V5-tag, CD2AP, CIN85, FLAG-tag, and a-tubulin antibodies. Arrows, CIN85
bands. D, Schematic presentation of the V5-tagged PHD2 variants used in GST pull-down studies: wt PHD2, PHD2 lacking amino acids 1-136 from the N-terminus
(DN), and PHD2 variant lacking amino acids 210–426 from the C-terminus (DC). E,Western blot analysis of pull downs using recombinant GST or GST fusion 3SH3
CIN85 protein in extracts from HEK-293 cells expressing V5-tagged PHD2 variants (wt, DN, or DC). Blots from pull downs were probed with V5-tag antibody;
inputs were probed with V5-tag and a-tubulin antibodies. Ponceau S stain of blots from pull downs was used as a loading control.
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(CD2AP). Although signiﬁcant differences between CIN85
and CD2AP, such as the presence of actin-binding sites in CD2AP
exist, there may be also similar binding properties that could
result in functional redundancies between the two family mem-
bers (21, 22). Thus, to examine whether CD2AP could be part of
the CIN85 and PHD2 complex, we probed the coimmunopreci-
pitation experiments for presence of CD2AP. The data show that
CD2AP appeared in the same complex with PHD2. However,
binding between PHD2 and CIN85 but not binding between
CD2AP and CIN85 was lost in the coimmunoprecipitations with
CIN85 constructs lacking all three SH3 domains. In contrast, we
lost binding of CD2AP but not binding of PHD2 upon usage of
the CIN85 construct lacking only the CC domain (Fig. 2C).
Together, these data indicate that the interaction of PHD2 with
CIN85 is mediated via the SH3 domains of CIN85 and not of
those fromCD2AP, and that binding between CIN85 and CD2AP
involves the CC domain.
Next, we investigated which part of PHD2 participates in the
binding to CIN85, and used, in addition to V5-tagged wt PHD2,
two constructs that allow the expression of either a V5-tagged N-
terminal part of PHD2 (V5-DC PHD2) or a V5-tagged C-terminal
part (V5-DN PHD2; Fig. 2D). In addition, because all three SH3
domains from CIN85 participate in the complex formation, we
used a recombinant GST-3SH3-CIN85 protein in pull-down
studies as bait for the PHD2 deletion variants (Fig. 2E). The
results of the pull-down assays show that GST-3SH3-CIN85 was
able to interact with wt PHD2 and the PHD2 variant lacking the
catalytic C-terminus (V5-DC PHD2). In contrast, no interaction
was observedwith a PHD2 lacking the ﬁrst 136 amino acids of the
N-terminus (V5-DN PHD2; Fig. 2E). Together, these data show
that the interaction betweenPHD2andCIN85occurs between the
three SH3 domains of CIN85 and the amino acids 1–136 within
the N-terminus of PHD2.
CIN85 binds a PR-rich sequence in the N-terminus of PHD2
To further delineate the CIN85-binding PHD2 region, we
generated a series of PHD2 coding constructs lacking various
amino acids from the N-terminus of PHD2 (Fig. 3A) and GST-
fusion proteins harboring peptides of different length from the
PHD2 N-terminus (Supplementary Fig. S2A and S2C). The latter
were used for pull downs with lysates of HEK-293 cells transiently
expressing full length Myc-CIN85 (Supplementary Fig. S2A and
S2C). As a result, GST-1-40-PHD2 and GST-99-136-PHD2 were
not able to pull down CIN85, indicating that amino acids 1–40
and 99–136 are not critical for the PHD2–CIN85 interaction
(Supplementary Fig. S2B). Other GST-PHD2 fragments used in
the studywere able tobindCIN85, although thebindingwasmost
evident when the amino acids 59–98 were present within the
PHD2 fragment. Further pull down studies with shorter GST-
PHD2 variants (Supplementary Fig. S2C) revealed that GST-81-
98-PHD2 showed the strongest binding to CIN85, while other
GST proteins were not able to pull down CIN85 to a similar level
(Supplementary Fig. S2D). Altogether the results of the pull down
studies indicated that the PHD2 region between amino acids 58–
98 is necessary for the binding toCIN85,whereas amino acids 81–
98 have the strongest impact on the interaction with CIN85.
Indeed, we observed similar results when using recombinant
GST-3SH3-CIN85 as bait in the lysates of HEK-293 cells tran-
siently expressing V5-tagged PHD2 variants lacking amino acids
from the N-terminus (Fig. 3A and B). While the PHD2 variants
D1–26, D10–58, D99–136, and D210–426 were able to bind
CIN85 like wt PHD2, the PHD2 variant lacking amino acids
52–98 showed an almost complete loss of binding like the PHD2
variant lacking the whole N-terminus (Fig. 3A and B; Supplemen-
tary Fig. S2E).
The SH3 domains of CIN85 are reported to recognize atypical
PR sequences (23) with each of the domains tolerating different
amino acid adjacent to the arginine residue. To further unravel the
nature of the CIN85-PHD2 binding, we aimed to identify the
proline and/or arginine residueswithin the regionbetween amino
acids 59–100 of PHD2 that are critical for the binding to CIN85.
To verify their involvement in the binding, we created several V5-
tagged PHD2 constructs where the respective proline or/and
arginine residues were mutated to alanines (referred to 6P mut,
PR mut1, and PR mut2; Fig. 3A). Pulldown studies with these
mutants andGST-3SH3-CIN85 revealed that these point-mutated
PHD2 variants lost almost all their binding to CIN85 when
compared with wt PHD2 (Fig. 3B). With the 6P mut variant,
where prolines 77, 78, 80, 84, 85, and 86 were substituted with
alanines, binding was decreased by about 60%. When PR mut1
(P86, R87, R91, P93, and R94 to alanine) was employed binding
was reduced by about 80%. Finally, the employment of PR mut2
(P86, P87, R91, P93, P94, R99, and R100 to alanine) reduced the
binding between PHD2 and CIN85 by about 90% (Supplemen-
tary Fig. S2E). Taken together, the results indicate that the proline
and arginine residues located within the area of amino acids 77–
100 in theN-terminus of PHD2 are critical for the interactionwith
the SH3 domains of CIN85.
PHD2 variants lacking CIN85-binding sequence show higher
catalytic activity
Because our previous ﬁndings indicated that CIN85 stabilizes
HIF1a levels via interference with PHD-dependentHIF1a protein
degradation, we investigated whether the ability of PHD2 to
interact with CIN85 has an impact on the catalytic activity of
PHD2. The results of an in vitro HIF1a peptide hydroxylation
assay (see Materials and Methods) with recombinant PHD2 as
catalyst revealed that addition of recombinant full-length CIN85
reduces the catalytic activity of PHD2 by about 70%. In contrast, a
CIN85 variant lacking the three SH3 domains involved in the
interaction with PHD2 did no longer reduce the PHD2 catalytic
activity. In addition, when we used the PHD2 variants with no or
the weakest binding to CIN85 (D52-98 PHD2; and PR mut2
PHD2, respectively) in the HIF1a peptide hydroxylation assay,
we observed that both PHD2 variants showed a higher activity
(about 15% and 20%, respectively) when compared with wt
PHD2. Furthermore, the activity of the PHD2 mutants was not
affected by the presence of CIN85 (Fig. 3C andD). In linewith the
results from the hydroxylation assay, overexpression of D52-98
and PR mut2 PHD2 increased the levels of hydroxy-HIF in
MG123-treated cells (Fig. 3E). Furthermore, overexpression of
D52-98 and PR mut2 PHD2 reduced HIF1a levels under both
normoxia and hypoxia, compared with wt PHD2 (Fig. 3F and G).
Together, these results suggest that lack of CIN85 binding pro-
motes PHD2 activity, and subsequently lowers HIFa levels.
Generation of MDA-MB-231 cells lacking the CIN85–PHD2
interaction
Next, we investigated the cellular impact of the CIN85–PHD2
interaction. To address this, we used the CRISPR/Cas9 approach
in triple-negative MDA-MB-231 breast cancer cells to edit the
EGLN1 (PHD2) gene in a manner that it encodes a PHD2 lacking
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Figure 3.
The PHD2 variants lacking the CIN85-binding pattern are of higher catalytic activity. A, Schematic presentation of the V5-tagged PHD2 deletion variants and V5-
tagged point-mutated PHD2 variants used in the pull downs: wt PHD2, 1–26 (D1–26 PHD2), 10–58 (D10–58 PHD2), 52–98 (D52–98 PHD2), 99–136 (D99–136
PHD2), 1–136 (D1–136 PHD2), 209–426 (D210–426 PHD2), PHD2 P77A, P78A, P80A, P84A, P85A, P86A (6P), PHD2 P86A, R87A, R91A, P93A, R94A (PRmut1), and
PHD2 P86A, P87A, R91A, P93A, P94A, R99A, R100A (PRmut2). B,Western blot analysis of pull downs using recombinant GST- 3SH3 CIN85 fusion proteins from
HEK-293 cells expressing V5-tagged PHD2 variants. Blots from pull downs were probed with V5-tag antibody; the input was probed with V5-tag and a-tubulin
antibodies. Ponceau S stain of pull downs was used as a loading control. C, Results of the in vitro hydroxylation assay using wt PHD2, D10–58 PHD2, and PRmut2
PHD2 as catalysts and a [3H]proline-labeled HIF1a peptide as a substrate in the presence of recombinant GST-CIN85 and GST-CIN85DSH3ABC. Recombinant
GST was used as a control. The amount of 4-hydroxy[3H]proline formed was analyzed by a radiochemical assay (see Materials and Methods) and used as a read
out of the PHD2 activity. Wt PHD2þGST was set to 100%. Data are mean SD (n¼ 3);  , signiﬁcant difference between D10–58 PHD2, and PRmut2 versus
wtPHD2; #, signiﬁcant difference between wt PHD2 and wt PHD2þ CIN85. D, Autoradiography of the [35S]Met-labeled wt PHD2, D10–58 PHD2, and PRmut2
PHD2 used in the hydroxylation assay. E, Hydroxy-HIF1a levels in MG132-treated cells expressing wt PHD2, D10–58 PHD2, and PRmut2 PHD2. F,Western blot
analysis of HEK-293 cells transiently expressing V5-tagged wt PHD2, D10–58 PHD2, and PRmut2 PHD2 cultured under normoxia (16%) or hypoxia (5% O2) for
6 hours. Extracts were probed with HIF1a, HIF2a, V5, and a-tubulin antibodies. G,Quantiﬁcation of HIF1a levels in HEK-293 cells transiently expressing empty
control vector (EV), V5-tagged wt PHD2, D10–58 PHD2, and PRmut2 PHD2 cultured under normoxia or hypoxia. HIF1a and HIF2a levels in empty control vector–
expressing cells cultured under hypoxia were set to 100%. Data are mean SD (n¼ 4);  , signiﬁcant difference between D10–58 PHD2, and PRmut2 PHD2-
expressing cells versus wt PHD2 (normoxia); #, signiﬁcant difference between HIF1a levels in wt PHD2, D10–58 PHD2, and PRmut2 PHD2-expressing cells versus
empty control vector–expressing cells (hypoxia).
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the amino acids required for binding to CIN85. By introducing
two double-strand breaks in EGLN1 exon 1, this approach
allowed deletion of 87 nucleotides (see Materials and Methods;
Supplementary Fig. S3A).
The results of genotyping indicated the presence of various gene
editing patterns after the introduction of Cas9 together with
EGLN1-sgRNA-219 and EGLN1-sgRNA-292 into MDA-MB-231
cells (Supplementary Fig. S3B). However, the respective PCR
products from two clones (E10 and E12) appeared as a single
band of the correct size on native PAGE. Furthermore, we
extracted total RNA from E10 and E12 cells and performed RT-
PCR using the same set of genotyping primers. The PCR products
fromboth clones appeared to be of shorter size comparedwith the
PCR product from S control cells (Supplementary Fig. S3C).
Afterwards, the PCR products from the gDNA and cDNA of both
clones were sequenced. As a result of sequencing, we observed
only one type of template from both E10 and E12 MDA-MB-231
cells, which harbored a homozygous deletion of 87 bp and
encodes a PHD2 variant lacking amino acids 75–103 (Supple-
mentary Fig. S3D). Next, by performing a Western blot analysis,
we were able to conﬁrm that the deletion of 87 bp in exon 1 of
EGLN1 allowed the expression of a smaller D75-103 PHD2 when
compared with the wt PHD2 in control scrambled cells (S;
Supplementary Fig. S3E).
Lack of amino acids 75–103 of PHD2 reduces HIFa levels
As a next step, we performed immunoprecipitations and GST-
pull downs using CIN85 antibodies and GST-3SH3-CIN85, and
veriﬁed that the PHD2–CIN85 interaction in the E10 and E12
MDA-MB-231 cells was lost (Fig. 4A and B).
Because our previous data showed that lack of the CIN85-
binding domain within PHD2 increases its activity and reduces
HIF1a (Fig. 3C–G), we now analyzed whether the lack of
the CIN85-binding site in the E10 and E12 cells increased
the levels of hydroxy-HIF1a. The data show that upon inhibi-
tion of the proteasomal degradation with MG132, increased
levels of hydroxy-HIF1a could be detected (Fig. 4C). Next,
we tested whether the edited cells would display reduced
protein levels of HIF1a and HIF2a under normoxia or hypoxia.
Indeed, HIF1a protein levels were reduced by about 50%–60%
in E10 and E12 cells compared with control S cells under
normoxia and by about 75% under hypoxia (Fig. 4D and E).
In addition, HIF2a protein levels were also downregulated in
E10 and E12 cells. While there was a trend for decreased HIF2a
levels under normoxic conditions, both E10 and E12 cells
showed about 60% lower HIF2a induction under hypoxia
(Fig. 4D and E).
In addition, we tested whether the reduction in HIFa levels has
consequences on the expression of HIF target genes. Indeed, loss
of the CIN85–PHD2 interaction in E10 and E12 cells reduced
expression of LDHA, GLUT1, VEGF, and CITED2 mRNA under
normoxia when compared with S cells and severely reduced their
hypoxia-dependent induction (Fig. 4F).
It is known, that hypoxia-triggered HIFa accumulation mainly
arises from a PHD-mediated decrease in HIF degradation, rather
than froman increase inmRNAexpression (20, 24). To investigate
whether thedownregulationofHIF1a andHIF2amay result from
a decrease in mRNA expression, we measured HIF1a and HIF2a
mRNA expression by qRT-PCR. We did not detect any signiﬁcant
changes in the expression of HIF1amRNA between S and E10 or
E12 cells (Supplementary Fig. S4A). However, clone E12
expressed lower levels of HIF2a mRNA compared with S cells
under normoxic conditions (Supplementary Fig. S4B).
To assess whether the absence of the amino acids 75–103 in the
engineered cells would lead to a changed expression of the
other PHD enzymes, we measured the protein levels of PHD1
and PHD3 by Western blot analysis. No differences were found
in the expression of PHD1 and PHD3 in E10 or E12 cells
(Supplementary Fig. S4C–S4E). In line with the results from the
Western blot analyses, E10 and E12 cells did not show changes on
the PHD1, PHD2, and PHD3 mRNA levels under normoxic
conditions compared with control cells (Supplementary
Fig. S4F–S4I). Because the expression levels of PHD1 and PHD3
were not changed in E10 and E12 cells (Supplementary Fig. S4F–
S4I), it is possible to conclude that that the observed down-
regulation in HIF1a and HIF2a levels is a result of the altered
PHD2. Altogether, these data show that the lack of CIN85–PHD2
interaction contributes to a decrease in HIFa levels.
Lack of amino acids 75–103 in PHD2mediates HIFa resistance
to CIN85 overexpression and attenuates EGF-mediated HIFa
induction
The abovementioned ﬁndings suggest that the HIFa levels in
the E10 and E12 cells could be resistant to overexpression of
CIN85 and that depletion of CIN85 could mimic the loss of the
CIN85–PHD2 interaction. To test this,weoverexpressedCIN85 in
S, E10, and E12 cells. The ﬁndings show that overexpression of
CIN85 increased HIF1a and HIF2a levels only in the S cells but
not in E10 and E12 cells (Fig. 5A and B). In addition, when we
knocked-down CIN85 with shRNA we observed that loss of
CIN85 decreased HIFa-levels only in S cells, whereas the already
lower HIF levels in E10 and E12 cells were not affected by the
knockdown of CIN85 (Supplementary Fig. S5A and S5B).
Because CIN85 has a prime function in the activation of
ERK1/2 and AKT in the EGF signaling pathway (11), we next
investigated whether the loss of the interaction between PHD2
and CIN85 in the E10 and E12 cells affects ERK1/2 and AKT
activation and induction of HIF1a and HIF2a in response to
EGF. The results show that neither basal nor EGF-dependent
activation of both ERK1/2 and AKT was altered in E10 and E12
cells when compared with S cells. In addition, EGF mediated an
increase in HIF1a levels in the S cells of about 5-fold under
normoxia. EGF was additive under hypoxia and enhanced
the hypoxia-dependent induction by about 2-fold. While EGF
also mediated about 5-fold induction of HIF2a in the S cells
under normoxia, no additive effect was seen under hypoxia.
Although EGF also caused an induction of both HIF1a and
HIF2a in E10 and E12 cells under normoxia; this induction was
less robust than in the S cells (Fig. 5C and D). Together, these
data suggest that the loss of the PHD2–CIN85 interaction is
rather selective for HIFa regulation and does not affect basal
and EGF-dependent ERK1/2 and AKT regulation.
Lack of amino acids 75–103 in PHD2 alters cell morphology
and contributes to less malignant cell properties
MDA-MB-231 is a triple-negative breast cancer cell line known
to have an aggressive metastatic phenotype. Therefore, we further
investigated whether the expression of D75–103 PHD2, and thus
the lack of CIN85–PHD2 interaction, contributed to any changes
inmorphology andmalignancy of these cells. To visualize the cell
shape and surface composition, we imaged S, E10, and E12 cells
by scanning electronmicroscopy (Supplementary Fig. S6A). Cells
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expressing D75-103 PHD2were elongated with fewer protrusions
on the leading edge of the cells. In addition, we investigated
whether the absence of amino acids 75–103 had an impact on
the intracellular localization of PHD2. Immunoﬂuorescence
revealed that D75–103 PHD2 did not change the cellular local-
ization. The distribution was mainly cytoplasmic, which was
similar to the wt PHD2 in S control cells. Visualization of
a-tubulin in S, E10, and E12 further veriﬁed the altered shape
and morphology of E10 and E12 cells, in line with the results of
the electron microscopy (Supplementary Fig. S6B). After observ-
ing the changes in cellular shape in E10 and E12 cells, we assessed
cellular proliferation, the ability to form colonies, the motility of
S, E10, and E12 cells, and tumor forming potential by injecting
these cells into nude mice.
When performing live-cell proliferation analyses using the
IncuCyte ZOOM System, we found that proliferation of the two
clones E10 and E12, expressing D75–103 PHD2 was slower than
that of MDA-MB-231 S control cells (Fig. 6A). While it took
72 hours for the control S cells to reach 100% conﬂuence, E10
cells were able to display the same conﬂuence level only after
108 hours, whereas E12 cells showed only 80% conﬂuence at the
end of a 117 hour experiment (Fig. 6A).
In addition, we evaluated cellular motility in a low-serum
wound (scratch) assay. Conﬂuent MDA-MB-231 control S, E10,
and E12 cells were wounded and wound closure was monitored
for 72 hours. In line with the data from proliferation assays, both
of the clones expressing D75–103 PHD2 were almost 50% less
motile than the control cells during wound closure. While
the control S cells were able to close the scratch area in about
24–30 hours, it took E10 and E12 cells about 12–18 hours and
26–32 hours longer, respectively (Fig. 6B and C).
The ability to grow and form colonies from single cells is a very
important malignant property of cancer cells. Therefore, we
performed colony formation assays by plating cells at very low
density and allowing them to grow for 10 days. Colony formation
was drastically impaired in E10 and E12 cells (Fig. 6D and E). The
number and size of colonies formed by control S cells was higher
than in E10 and E12 cells. In addition, the colonies of control cells
were dense and displayed an overlapping growth pattern, while
E10 and E12 cells were disseminated within the colony (Fig. 6D
and E). Although the decrease in colony formation with the E10
and E12 cells was signiﬁcant, some of the difference may also be
due to the reduction in proliferation.
We next tested whether the observed reduced proliferation
and impaired migration of E10 and E12 cells are the result of
the increased PHD2 activity and reduced HIF1a levels. To do
this, we treated the cells with the HIF-PHD inhibitor, FG-4592
(roxadustat), or transfected the cells with either HIF1a or PHD2
expression vectors. Treatment of cells with FG-4592 stabilized
HIF1a and counteracted the reduced proliferation and migration
in E10 and E12 cells without having signiﬁcant effects in control S
cells (Supplementary Fig. S7A–S7F). Although overexpression
of HIF1a promoted proliferation, as well as migration in all cells,
its action was more pronounced in E10 and E12 cells. Like with
FG-4592, this abolished the differences in proliferation and
wound healing in E10 cells and largely also in E12 cells
Figure 4.
Lack of amino acids 75–103 within PHD2 reduces HIFa levels in MDA-MB-231
cells. A, Immunoprecipitations (IP) were performed with the CIN85 antibody
from control S, E10, and E12 cells and probed for PHD2 and CIN85. Blots from
the input were probed with CIN85, PHD2, and a-tubulin antibody. B,Western
blot analysis of pull downs using recombinant GST and GST-fusion 3SH3
CIN85 proteins in MDA-MB-231 control S, E10, and E12 cells. Blots from pull
downs were probed with PHD2 antibody; blots from the input were probed
with PHD2 and a-tubulin antibodies. Ponceau S stain was used as a loading
control. C, Hydroxy-HIF1a levels in MG132-treated control S, E10, and E12
cells. Extracts were probed with OH-HIF1a, PHD2, and a-tubulin antibodies.
D, HIF1a and HIF2a levels in control S, E10, and E12 cells cultured under
normoxia (16%) or hypoxia (5% O2) for 6 hours. Blots were probed with HIF1a,
HIF2a, and a-tubulin antibodies. E,Quantiﬁcation of HIF1a and HIF2a levels
in control S, E10, and E12 cells, cultured under normoxia or hypoxia. HIF1a and
HIF2a levels in S cells cultured under hypoxia were set to 100%. Data are
mean SD (n¼ 4);  , signiﬁcant difference between E10 and E12 cells versus
control (normoxia); #, signiﬁcant difference between E10 and E12 cells versus
control S cells (hypoxia). F,Quantiﬁcation of LDHA, GLUT1, CITED2, and
VEGFmRNA levels in control S, E10, and E12 cells cultured under normoxia or
hypoxia. The respective mRNA levels in control S cells cultured under
normoxia were set to 1. Data are mean SD (n¼ 3);  , signiﬁcant difference
between E10 and E12 cells versus control (normoxia); #, signiﬁcant difference
between E10 and E12 cells versus control S cells (hypoxia).
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(Supplementary Fig. S7G and S7H). In contrast, overexpression of
full length PHD2 inhibited proliferation and wound healing
signiﬁcantly only in S cells and marginally but insigniﬁcantly in
E10 and E12 cells (Supplementary Fig. S7G and S7H). Because the
observed changes were not attributable to the off-target effects of
the CRISPR/Cas9-mediated EGLN1 gene editing (Supplementary
Fig. S8A–S8L), these ﬁndings support the view that the observed
cellular phenotypes of E10 and E12 cells are largely dependent on
both, the activity of PHD2 and HIF1a.
Because the abovementioned assays pointed to a lessmalignant
phenotype of E10 and E12 cells compared with control S cells, we
next investigated whether these characteristics are also present
in vivo. Therefore, we transplanted MDA-MB-231 control S versus
E10 and S versus E12 cells, into the thoracic and inguinal mam-
mary fat pads of 18 female athymic immune-deﬁcient nude mice
and followed tumor growth by palpation and size measurement
for up to 8 weeks. Although all cells were able to form tumors in
these mice, it was obvious that the arisen tumors from control
S cells were of bigger volume, compared with tumors formed
from E10 and E12 cells (Fig. 6F andG). While the average volume
of tumors from control S cells was about 138 mm3 at the time of
necropsy, the E10- andE12-derived tumorshad a volumeof about
36mm3 and 44mm3, respectively (Fig. 6F–H).We also noted that
the E10- and E12 cell–derived tumors were paler when compared
with the tumors formed fromcontrol S cells,which is likely a result
from reduced angiogenesis due to lower HIFa levels (Fig. 6F–H).
Collectively, these data show that MDA-MB-231 cells expres-
sing D75–103 PHD2, and thus lacking the interaction between
PHD2 and CIN85, are less motile, have a lower proliferative, as
well as tumor forming potential.
Figure 5.
Lack of the CIN85–PHD2 interaction in MDA-MB-231 cells mediates HIFa resistance to CIN85 overexpression and attenuates EGF-mediated HIFa induction.
A,Quantiﬁcation of HIF1a and HIF2a levels in MDA-MB-231 control S, E10, and E12 cells transfected with empty vector (þCtr) and in S, E10, and E12 cells with
overexpression of CIN85 (þCIN85). Cells were cultured under normoxia (16%) or hypoxia (5% O2) for 4 hours. HIF1a and HIF2a levels in S (þCtr) cells under
hypoxia were set to 100%. Data are meanSD (n¼ 4);  , signiﬁcant difference between E10 and E12 cells versus S (þCtr, normoxia); #, signiﬁcant difference
between E10 and E12 cells versus S cells (þCtr, hypoxia); #, signiﬁcant differences S (þCtr) versus S (þCIN85) under normoxia and hypoxia. B,Western blot
analysis. Blots were probed with HIF1a, HIF2a, PHD2, CIN85, and a-tubulin antibodies. C,Quantiﬁcation of HIF1a and HIF2a levels in control S, E10, and
E12 cells treated with vehicle (Ctr) or EGF (100 ng/mL). HIF1a and HIF2a levels in S (þCtr) cells under hypoxia were set to 100%. Data are meanSD (n¼ 3);
 , signiﬁcant difference between vehicle (Ctr)-treated S, E10 and E12 cells versus EGF-treated S, E10, and E12 cells (normoxia); #, signiﬁcant difference between
vehicle (Ctr)-treated S, E10, and E12 cells versus EGF-treated S, E10, and E12 cells (hypoxia).D,Western blot analysis. Blots were probed with antibodies against
HIF1a, HIF2a, pERK, total ERK, pAKT, total AKT, PHD2, and tubulin.
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Discussion
This investigation shows that the prooncogenic adaptor pro-
tein, CIN85, is a novel inhibitory binding partner of PHD2
(Fig. 1). We deﬁned the nature of CIN85–PHD2 complex forma-
tion by revealing the importance of the three N-terminal SH3
domains of CIN85 and the proline and arginine residues within
the N-terminus of PHD2, lying outside of the zinc-ﬁnger domain
of PHD2 (Figs. 2 and 3). By performing CRISPR/Cas9-mediated
EGLN1 gene editing, we created MDA-MB-231 cell lines,
Figure 6.
Lack of amino acids 75–103 in PHD2 reduces malignant properties of MDA-MB-231 cells. A, Live cell proliferation analysis of MDA-MB-231 control S, E10, and E12
cells (see Material and Methods). Data are mean SD (n¼ 5);  , signiﬁcant difference between relative conﬂuence values of D75-103 PHD2-expressing cells (E10
and E12) versus control S cells at each timepoint. B, Representative images of the wound closure of control S, E10, and E12 cells at 0, 12, and 24 hours timepoint
after introduction of the wound. Scale bar, 300 mm. C, Live cell wound closure analysis of MDA-MB-231 S, E10, and E12 cells (see Material and Methods). Data are
mean SD (n¼ 4);  , signiﬁcant difference between wound conﬂuence values of D75-103 PHD2-expressing cells (E10 and E12) versus control S cells at each
timepoint. D, Representative images of the whole-cell culture wells and single colonies formed by MDA-MB-231 S, E10, and E12 cells. Scale bar, 1 mm. E,
Quantiﬁcation of the colony formation assay. The total number of colonies per well was set to 1 in control S cells. Data are mean SD (n¼ 4);  , signiﬁcant
difference between the number of colonies formed by E10 and E12 cells versus control S cells. MDA-MB-231 control S, E10, and E12 cells were injected into the
thoracic and inguinal mammary fat pads of female athymic nudemice (6 animals per group). F and G, Representative image of tumors derived from control S
versus E10 (F) and control S versus E12 (G). H, Boxplot indicating the respective volume differences of the control S–derived tumors compared with the E10- and
E12-derived tumors. Center lines, medians; crosses, sample means; gray bars within boxes, 83% conﬁdence intervals of the means; the box limits indicate the 25th
and 75th percentiles as determined by R software; whiskers extend to minimum andmaximum values; data points are plotted as open circles. Number¼ 30, 10,
13 tumor sample points.  , signiﬁcant difference of the means S versus E10 and E12.
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expressing a PHD2 lacking amino acids 75–103, which was
unable to bind CIN85 (Fig. 4). The abrogation of the PHD2–
CIN85 interaction led to lower HIF1a and HIF2a levels (Figs. 4
and 5), thus contributing to a less malignant phenotype of MDA-
MB-231 cells (Fig. 6).
Interestingly, from three HIF-regulating PHDs, CIN85 binds
only PHD2 because PHD2, unlike PHD1 and 3, contains an
extended N-terminus with the MYND-zinc-ﬁnger part, and as
shown here the atypical SH3 domain docking sites. In fact, BLAST
results show that PHD2 shares only similarity with the other
PHDs in the catalytic domains, where amino acids 192–417 of
PHD2 share a 68% identity with amino acids 176–403 of the
catalytic domain of PHD1. PHD3's amino acids 2–225 share an
overall identity of 64%with PHD2, which resides between amino
acids 181–403 of PHD2.
In addition, this study also shows that a close relative of CIN85,
CD2AP can be in complex with CIN85 and PHD2 (Fig. 2C);
however, the complex formation is facilitated by different inter-
actions between the proteins. It appears that the SH3 domains of
CIN85 and the N-terminus of PHD2 interact, as well as the CC
domain of CIN85with CD2AP. This supports the earlier view that
anumber of nonredundant functions betweenCIN85andCD2AP
exist (25). Indeed, CD2AP differs from CIN85 by the presence of
additional actin-binding sites before the CC domain (26), and by
the lack of one proline-rich segment and the PEST sequence
proximal to the CC domain (25). Moreover, a recent publication
employing detailed biophysical analyses has shown that, apart
from the CC domain, important differences in the orientation of
the SH3 domains of CD2AP and CIN85 upon interaction with
their partners exist (27). Thus, these differences may account for
the observeddistinct biological behavior toward PHD2and imply
that the context, in particular that of the binding partner, is
important and that there is no single, exact motif in the target
molecules binding the SH3 domains. There is rather a core of
critical residues in the binding partner, whichdiffer with respect to
the type of residues in ﬂanking positions mediating the binding.
Thus, the sequence context of the binding partner, for example,
PHD2 appear to dictate which residues determine its interaction
potential. Hence, even if the difference in sequence and structure
between the SH3domains betweenCIN85 andCD2AP appears to
be minimal, the difference in afﬁnity for the binding interface
might be rather large. For example, if a Lys (e.g., K114 in CD2AP)
is replaced by a charge-neutral amino acid (e.g., Q 104) in CIN85,
the structure difference may be minimal, but the difference in
afﬁnity for the interface at the binding partner might be rather
large. This is underlined by a recent study employing ﬂanking
residue permutation arrays in the CD2AP-binding protein, ALIX,
where selectivity could be achieved even between the three SH3
domains (28). Similar effects were also reported for the CIN85
SH3 domains (29). After all, a possibly minimal structural dif-
ference can become clearly signiﬁcant for the observed behavior
(binding), butmay probably not verymuch affect another type of
behavior (e.g., solubility). Thus, there might be some functional
redundancy but also quite a lot of difference between the function
of CIN85 andCD2APwhere these contexts need to be considered.
This is further exempliﬁed by ﬁndings from mice and humans,
indicating that CIN85 andCD2AP have indeed distinct functions.
In particular, a germline deletion within the CIN85 gene on the
human X chromosome caused antibody deﬁciency due to defects
in B lymphocyte effector pathways such as NF-kB and upregula-
tion ofCD86 expression (30). In contrast, SNPs or deletions of the
CD2AP gene led to abnormal kidney function and proteinuria
with nephrotic syndrome caused by focal segmental glomerulo-
sclerosis (31). Overall, these data, in line with this study, suggest
that there are a number of nonredundant functions in the action
of CIN85 and CD2AP.
The overexpression of CIN85 is known to inﬂuence the devel-
opment andprogression of various types of cancers, amongwhich
are carcinomas of the head and neck (32), cervix (33), and
colon (12). Our own research showed that CIN85 is highly
overexpressed in breast carcinoma (11), and contributes to breast
cancer pathogenesis via the attenuation of EGFR andErbB2/HER2
downregulation (11, 34). In addition, the mechanisms behind
CIN85-driven carcinogenesis include an enhancement of TGF-b
signaling and promotion of cell invasiveness via focal adhesion
kinase (35). Moreover, our previous ﬁndings indicated that
CIN85 contributes to cancer progression via stabilization of
HIF1/2a (as well as the expression of HIF target genes such as
PAI-1; ref. 13). This study extended theseﬁndings and veriﬁed that
the direct interaction of CIN85 and PHD2 can inhibit PHD2-
mediated prolyl-hydroxylation of HIFa subunits.
The HIF family of transcription factors are essential molecular
regulators of normal development and at the same time serve as
crucial contributors to the progression of various types of can-
cers (36). Although HIFa levels are regulated via multiple
mechanisms (3), the hydroxylation-dependent mechanism is
considered to have a major impact on HIF1a degradation. All
members of the HIF-PHD family are able to hydroxylate HIF1a
in vitro (37); however, PHD2 is found to be the most important
hydroxylase to regulate HIF1a levels under normoxic condi-
tions (20, 24). The activity of PHD2 is critical for HIFa stability;
however, alterations in the enzymatic function of PHD2 are not
always caused by the lack of oxygen (38). The enzymatic function
of PHD2 can be indirectly altered through the association with
other proteins that interfere with the PHD2/HIFas/VHL complex
formation.
The majority of PHD2 interactors contribute to the down-
regulation ofHIFa levels. For example, inhibitor of growth family
member 4 (ING4; ref. 39), p23 from the HSP90 machinery (40),
and the runt-domain transcription factor (41) were reported to
promote the association between PHD2 and HIFa that leads to a
faster downregulation of HIF1a. Another example is the direct
interaction of the adaptor proteins LIMD1 and RHO-related BTB
domain-containing protein 3 (RHOBTB3) with PHD2 and VHL
simultaneously (42). The association of PHD2 with these
adaptors promotes the assembly of hydroxylation-dependent
degradation machinery, which further contributes to lower levels
of bothHIF1a andHIF2a (42). Because decreased levels of HIFas
are usually considered to favor patient survival, the participation
of RUNX3 (43), ING4 (44), LIMD1 (45), and RHOBTB3 (46) in
downregulating HIFas additionally conﬁrms the known tumor-
suppressing role of these proteins in human cancers. Interestingly,
our data show that the strength of the interaction between PHD2
and CIN85 varies between the cell lines investigated. This could
suggest that (an)other factor(s), existence of which could vary
between the different cell types, may contribute to the strength
of the interaction and future studies will show whether this is
the case.
The results of our study indicate that the interaction of CIN85
with PHD2 leads to a very different outcome by contributing to
the increased stability of HIF1a and HIF2a. Our current investi-
gation describes a direct interaction with PHD2 as a mechanism
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by which CIN85 regulates HIF1a and HIF2a stability in breast
cancer cells. This event appears to occur in the cytoplasm because
we found that the CIN85–PHD2 interaction was predominantly
cytoplasmic (Fig. 1). This is in line with reports that, both PHD2
and CIN85 are cytoplasmic proteins although PHD2 has also
been found in the nucleus (47). In addition, we showed that
CIN85 utilizes three SH3 domains to facilitate the binding to
PHD2 (Fig. 2).
While the majority of SH3 domains bind "typical" proline-rich
motifs like PXXP (where X is any amino acid), the SH3domains of
CIN85 are reported to recognize atypical PR sequences (23). By
using a variety of PHD2 and CIN85 constructs in immunopre-
cipitation and GST-pull down experiments, we found that a
PR-rich area between amino acids 77–100 is the most important
for the direct interaction with CIN85 (Figs. 1–3).
While PHD2-binding partners are known to utilize either the
Zn-MYND ﬁnger domain (48), or the catalytic domain of PHD2,
we deﬁne CIN85 as the ﬁrst interactor recognizing a different
binding motif in the sequence of PHD2 (Fig. 3). The mapping of
the binding motif for CIN85 not only identiﬁed critical residues
mediating the CIN85–PHD2 complex formation, but also
revealed the existence of a functional sequence in the N-terminus
of PHD2 able to mediate protein–protein interactions. Although
this approachwas straight forward, there exists also the possibility
that the systematic mutation of the proline residues may have led
to a conformational change in PHD2 in other regions, thus
inﬂuencing the binding between CIN85 and PHD2 indirectly.
Interestingly, the PHD2variants lacking the ability to interactwith
CIN85 showed higher catalytic activity in the in vitro hydroxyl-
ation assay, thus leading to lower levels of HIF1a. Although the
structural basis for oxygen degradation domain selectivity of the
catalytic PHD regions are quite well known (49), the crystal
structural details of the PHD2 N-terminus harboring the CIN85
interaction site remain so far unresolved. However, the current
data are in line with earlier ﬁndings showing that the N-terminus
of PHD2 is inhibitory (50). This, in line with the in vitro hydrox-
ylation assays of this study, suggests that binding of CIN85might
regulate PHD2 activity at the N-terminus by reducing the acces-
sibility of its catalytic domain to a substrate.
After establishing the binding pattern between CIN85 and
PHD2, we created a cell system lacking this molecular interplay
using CRISPR/Cas9-mediated EGLN1 gene editing. Two indepen-
dent cell clones expressing PHD2-lacking amino acids 75–103
and consequently the interaction between CIN85 and PHD2were
generated (Fig. 4). The MDA-MB-231 D75–103 PHD2-expressing
cell lines E10 and E12 showed, as expected, lower HIF1a and
HIF2a protein levels (Fig. 5), and slower proliferation, decreased
motility, as well as a reduced tumor forming potential in nude
mice when compared with the respective control cells (Fig. 6).
Our previous ﬁndings indicated that overexpression of CIN85
stabilizes HIF1a levels, and notably, that downregulation of
CIN85 reversed this effect (13). The results of this study allow
us to conclude that lower HIF1a levels under normoxic condi-
tions inD75–103 PHD2-expressing cells originate fromdecreased
protein stability and cannot be attributed to the differences in
HIFa mRNA expression. In addition, we can associate the
observed downregulation in HIF1a and HIF2a levels with
D75–103 PHD2 function, because the expression of the two
other PHDs (PHD1 and PHD3) was not affected (Supplementary
Fig. S4A–S4I).
Altogether, our study is theﬁrst to describe the relation between
PHD2 and CIN85. We identiﬁed CIN85 as a novel inhibitory
binding partner of PHD2, able to increase HIFa levels and, thus,
to promote HIFa stability and breast cancer malignancy.
Disclosure of Potential Conﬂicts of Interest
No potential conﬂicts of interest were disclosed.
Authors' Contributions
Conception and design: N. Kozlova, L.B. Drobot, T. Kietzmann
Development of methodology: N. Kozlova, E.Y. Dimova, E. Biterova,
A. Hassinen, A. Manninen, L.B. Drobot, T. Kietzmann
Acquisition of data (provided animals, acquired and managed patients,
provided facilities, etc.): N. Kozlova, A. Samoylenko, P. Koivunen,
E. Biterova, K. Richter, A. Hassinen, I. Miinalainen, V. Glumoff, T. Kietzmann
Analysis and interpretation of data (e.g., statistical analysis, biostatistics,
computational analysis): N. Kozlova, A. Samoylenko, I. Miinalainen,
L. Ruddock, T. Kietzmann
Writing, review, and/or revision of themanuscript:N. Kozlova, D.Mennerich,
A. Samoylenko, S. Kellokumpu, I. Miinalainen, L. Ruddock, L.B. Drobot,
T. Kietzmann
Administrative, technical, or material support (i.e., reporting or organizing
data, constructing databases): N. Kozlova, S. Kellokumpu, A. Manninen,
T. Kietzmann
Study supervision: T. Kietzmann
Acknowledgments
The authors are grateful to Dr. Svetlana Marchenko for help with the
GST pull-down experiments in the beginning of the study, Dr. Kristian Koski
for help with protein puriﬁcation, Jaana Tr€askelin and Dr. Satu Myllym€aki
for help with the production of lentiviral particles, and Lea Boten, Jonas
B€ohm, Lea Cleve, Anabel Arnemann (School of Life Science Hamburg,
Germany), and Maire Jarva for excellent technical assistance. The work in
the authors' laboratories was supported by grants from the Federation of
European Biochemical Societies (to N. Kozlova), Finnish Center of Inter-
national Mobility (to T. Kietzmann), Finnish Academy of Sciences
(SA296027 to T. Kietzmann and SA308009 to P. Koivunen), Jane and Aatos
Erkko Foundation (to T. Kietzmann and P. Koivunen), Finnish Cancer
Foundation (to T. Kietzmann and P. Koivunen), Sigrid Juselius Foundation
(to T. Kietzmann, P. Koivunen, and L. Ruddock), Biocenter Oulu (to T.
Kietzmann, P. Koivunen, A. Manninen, I. Miinalainen, and L. Ruddock), and
University of Oulu supported this work.
The costs of publication of this articlewere defrayed inpart by the payment of
page charges. This article must therefore be hereby marked advertisement in
accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received December 11, 2018; revised April 17, 2019; accepted May 24, 2019;
published ﬁrst May 29, 2019.
References
1. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2
(neu) signaling increases the rate of hypoxia-inducible factor 1alpha
(HIF-1alpha) synthesis: Novel mechanism for HIF-1-mediated vascu-
lar endothelial growth factor expression. Mol Cell Biol 2001;21:
3995–4004.
2. Semenza GL. Molecular mechanisms mediating metastasis of hypoxic
breast cancer cells. Trends Mol Med 2012;18:534–43.
3. Flugel D, Gorlach A, Kietzmann T. GSK-3beta regulates cell growth,
migration, and angiogenesis via Fbw7 and USP28-dependent degradation
of HIF-1alpha. Blood 2012;119:1292–301.
4. Ivan M, Haberberger T, Gervasi DC, Michelson KS, Gunzler V, Kondo K,
et al. Biochemical puriﬁcation and pharmacological inhibition of a mam-
malian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl
Acad Sci U S A 2002;99:13459–64.
Kozlova et al.
Cancer Res; 79(16) August 15, 2019 Cancer Research4054
on October 25, 2019. © 2019 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Published OnlineFirst May 29, 2019; DOI: 10.1158/0008-5472.CAN-18-3852 
5. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, et al.
Targeting ofHIF-alpha to the von hippel-lindau ubiquitylation complex by
O2-regulated prolyl hydroxylation. Science 2001;292:468–72.
6. Soubeyran P, Kowanetz K, Szymkiewicz I, Langdon WY, Dikic I. Cbl-
CIN85-endophilin complex mediates ligand-induced downregulation of
EGF receptors. Nature 2002;416:183–7.
7. Minegishi Y, Shibagaki Y,Mizutani A, Fujita K, Tezuka T, KinoshitaM, et al.
Adaptor protein complex of FRS2ß and CIN85/CD2AP provides a novel
mechanism for ErbB2/HER2 protein downregulation. Cancer Sci 2013;
104:345–52.
8. Petrelli A, Gilestro GF, Lanzardo S, Comoglio PM, Migone N, Giordano S.
The endophilin-CIN85-cbl complex mediates ligand-dependent down-
regulation of c-met. Nature 2002;416:187–90.
9. Havrylov S, Redowicz MJ, Buchman VL. Emerging roles of Ruk/CIN85 in
vesicle-mediated transport, adhesion, migration and malignancy. Trafﬁc
2010;11:721–31.
10. Nam JM,Onodera Y,Mazaki Y,Miyoshi H, Hashimoto S, SabeH. CIN85, a
cbl-interacting protein, is a component of AMAP1-mediated breast cancer
invasion machinery. EMBO J 2007;26:647–56.
11. Samoylenko A, Vynnytska-Myronovska B, Byts N, Kozlova N, Basaraba O,
Pasichnyk G, et al. Increased levels of the HER1 adaptor protein Rukl/
CIN85 contribute to breast cancer malignancy. Carcinogenesis 2012;33:
1976–84.
12. Cascio S, Finn OJ. Complex of MUC1, CIN85 and cbl in colon cancer
progression and metastasis. Cancers 2015;7:342–52.
13. Samoylenko A, Dimova EY, Kozlova N, Drobot L, Kietzmann T. The
adaptor protein Ruk/CIN85 activates plasminogen activator inhibitor-1
(PAI-1) expression via hypoxia-inducible factor-1alpha. ThrombHaemost
2010;103:901–9.
14. Kerppola TK. Design and implementation of bimolecular ﬂuorescence
complementation (BiFC) assays for the visualization of protein interac-
tions in living cells. Nat Protoc 2006;1:1278–86.
15. Gout I, Middleton G, Adu J, Ninkina NN, Drobot LB, Filonenko V, et al.
Negative regulation of PI 3-kinase by Ruk, a novel adaptor protein. EMBO J
2000;19:4015–25.
16. Scharf JG, Unterman TG, Kietzmann T. Oxygen-dependent modulation of
insulin-like growth factor binding protein biosynthesis in primary cultures
of rat hepatocytes. Endocrinology 2005;146:5433–43.
17. Mayevska O, Shuvayeva H, Igumentseva N, Havrylov S, Basaraba O,
Bobak Y, et al. Expression of adaptor protein Ruk/CIN85 isoforms in
cell lines of various tissue origins and human melanoma. Exp Oncol
2006;28:275–81.
18. Hirsila M, Koivunen P, Gunzler V, Kivirikko KI, Myllyharju J. Character-
ization of the human prolyl 4-hydroxylases that modify the hypoxia-
inducible factor. J Biol Chem 2003;278:30772–80.
19. Konzack A, Jakupovic M, Kubaichuk K, Gorlach A, Dombrowski F, Mii-
nalainen I, et al. Mitochondrial dysfunction due to lack of manganese
superoxide dismutase promotes hepatocarcinogenesis. Antioxid Redox
Signal 2015;23:1059–75.
20. Berra E, Benizri E, Ginouves A, Volmat V, Roux D, Pouyssegur J. HIF prolyl-
hydroxylase 2 is the key oxygen sensor setting low steady-state levels ofHIF-
1alpha in normoxia. EMBO J 2003;22:4082–90.
21. Kirsch KH,GeorgescuMM, Shishido T, LangdonWY, Birge RB,HanafusaH.
The adapter type protein CMS/CD2AP binds to the proto-oncogenic
protein c-cbl through a tyrosine phosphorylation-regulated Src homology
3 domain interaction. J Biol Chem 2001;276:4957–63.
22. Dikic I. CIN85/CMS family of adaptor molecules. FEBS Lett 2002;529:
110–5.
23. Kurakin AV,Wu S, BredesenDE. Atypical recognition consensus of CIN85/
SETA/Ruk SH3 domains revealed by target-assisted iterative screening.
J Biol Chem 2003;278:34102–9.
24. Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW, et al.
Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3
in the regulation of hypoxia-inducible factor. J Biol Chem 2004;279:
38458–65.
25. Tibaldi EV, Reinherz EL. CD2BP3, CIN85 and the structurally related
adaptor protein CMS bind to the same CD2 cytoplasmic segment, but
elicit divergent functional activities. Int Immunol 2003;15:313–29.
26. Gaidos G, Soni S, Oswald DJ, Toselli PA, Kirsch KH. Structure and
function analysis of the CMS/CIN85 protein family identiﬁes actin-
bundling properties and heterotypic-complex formation. J Cell Sci
2007;120:2366–77.
27. Ceregido MA, Garcia-Pino A, Ortega-Roldan JL, Casares S, Lopez Mayorga
O, Bravo J, et al.Multimeric anddifferential binding ofCIN85/CD2APwith
two atypical proline-rich sequences fromCD2and cbl-b. FEBS J 2013;280:
3399–415.
28. Rouka E, Simister PC, Janning M, Kumbrink J, Konstantinou T, Muniz JR,
et al. Differential recognition preferences of the three Src homology 3
(SH3) domains from the adaptor CD2-associated protein (CD2AP) and
direct association with ras and rab interactor 3 (RIN3). J Biol Chem 2015;
290:25275–92.
29. Ababou A, Pfuhl M, Ladbury JE. Novel insights into the mechanisms of
CIN85 SH3 domains binding to Cbl proteins: Solution-based investiga-
tions and in vivo implications. J Mol Biol 2009;387:1120–36.
30. Keller B, Shoukier M, Schulz K, Bhatt A, Heine I, Strohmeier V, et al.
Germline deletion of CIN85 in humans with X chromosome-linked
antibody deﬁciency. J Exp Med 2018;215:1327–36.
31. Takano T, Bareke E, Takeda N, Aoudjit L, Baldwin C, Pisano P, et al.
Recessivemutation inCD2AP causes focal segmental glomerulosclerosis in
humans and mice. Kidney Int 2019;95:57–61.
32. Wakasaki T, MasudaM,NiiroH, Jabbarzadeh-Tabrizi S, Noda K, Taniyama
T, et al. A critical role of c-Cbl-interacting protein of 85 kDa in the
development and progression of head and neck squamous cell carcinomas
through the ras-ERK pathway. Neoplasia 2010;12:789–96.
33. Ma Y, Ye F, Xie X, Zhou C, Lu W. Signiﬁcance of PTPRZ1 and CIN85
expression in cervical carcinoma. Arch Gynecol Obstet 2011;284:
699–704.
34. Schroeder B, Weller SG, Chen J, Billadeau D, McNivenMA. ADyn2-CIN85
complex mediates degradative trafﬁc of the EGFR by regulation of late
endosomal budding. EMBO J 2010;29:3039–53.
35. Schmidt MHH, Chen B, Randazzo LM, B€ogler O. SETA/CIN85/Ruk and
its binding partner AIP1 associate with diverse cytoskeletal elements,
including FAKs, and modulate cell adhesion. J Cell Sci 2003;116:
2845–55.
36. Dales JP, Garcia S, Meunier-Carpentier S, Andrac-Meyer L, Haddad O,
Lavaut MN, et al. Overexpression of hypoxia-inducible factor HIF-1a
predicts early relapse in breast cancer: Retrospective study in a series of
745 patients. Int J Cancer 2005;116:734–9.
37. Koivunen P, Tiainen P, Hyvarinen J, Williams KE, Sormunen R, Klaus SJ,
et al. An endoplasmic reticulum transmembrane prolyl 4-hydroxylase is
induced by hypoxia and acts on hypoxia-inducible factor alpha. J Biol
Chem 2007;282:30544–52.
38. Stolze IP, Mole DR, Ratcliffe PJ. Regulation of HIF: prolyl hydroxylases.
Novartis Found Symp 2006;272:15–25.
39. Colla S, Tagliaferri S, Morandi F, Lunghi P, Donofrio G, Martorana D, et al.
The new tumor-suppressor gene inhibitor of growth family member 4
(ING4) regulates the production of proangiogenic molecules by myeloma
cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activ-
ity: involvement in myeloma-induced angiogenesis. Blood 2007;110:
4464–75.
40. Song D, Li LS, Heaton-Johnson KJ, Arsenault PR, Master SR, Lee FS. Prolyl
hydroxylase domain protein 2 (PHD2) binds a Pro-Xaa-Leu-Glu motif,
linking it to the heat shock protein 90 pathway. J Biol Chem 2013;288:
9662–74.
41. Lee SH, Bae SC, Kim KW, Lee YM. RUNX3 inhibits hypoxia-inducible
factor-1a protein stability by interacting with prolyl hydroxylases in gastric
cancer cells. Oncogene 2014;33:1458–67.
42. Foxler DE, Bridge KS, James V, Webb TM, Mee M, Wong SC, et al. The
LIMD1 protein bridges an association between the prolyl hydroxylases and
VHL to repress HIF-1 activity. Nat Cell Biol 2012;14:201–8.
43. Yu YY, Chen C, Kong F-, Zhang W. Clinicopathological signiﬁcance and
potential drug target of RUNX3 inbreast cancer.DrugDesDevTher 2014;8:
2423–30.
44. Ozer A, Bruick RK. Regulation of HIF by prolyl hydroxylases: recruit-
ment of the candidate tumor suppressor protein ING4. Cell Cycle 2005;
4:1153–6.
45. Sharp TV, Munoz F, Bourboulia D, Presneau N, Darai E, Wang HW, et al.
LIM domains-containing protein 1 (LIMD1), a tumor suppressor encoded
at chromosome 3p21.3, binds pRB and represses E2F-driven transcription.
Proc Natl Acad Sci U S A 2004;101:16531–6.
CIN85 Inhibits the Function of PHD2
www.aacrjournals.org Cancer Res; 79(16) August 15, 2019 4055
on October 25, 2019. © 2019 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Published OnlineFirst May 29, 2019; DOI: 10.1158/0008-5472.CAN-18-3852 
46. Zhang CS, Liu Q, Li M, Lin SY, Peng Y, Wu D, et al. RHOBTB3 promotes
proteasomal degradation of HIFa through facilitating hydroxylation and
suppresses the Warburg effect. Cell Res 2015;25:1025–42.
47. Pientka FK, Hu J, Schindler SG, Brix B, Thiel A, J€ohren O, et al. Oxygen
sensing by the prolyl-4-hydroxylase PHD2 within the nuclear compart-
ment and the inﬂuence of compartmentalisation onHIF-1 signalling. J Cell
Sci 2012;125:5168–76.
48. Barth S, Edlich F, Berchner-Pfannschmidt U, Gneuss S, Jahreis G, Hasgall
PA, et al. Hypoxia-inducible factor prolyl-4-hydroxylase PHD2 protein
abundance depends on integral membrane anchoring of FKBP38. J Biol
Chem 2009;284:23046–58.
49. Chowdhury R, Leung IK, Tian YM, Abboud MI, Ge W, Domene C, et al.
Structural basis for oxygendegradation domain selectivity of theHIF prolyl
hydroxylases. Nat Commun 2016;7:12673.
50. Choi KO, Lee T, Lee N, Kim JH, Yang EG, Yoon JM, et al. Inhibition
of the catalytic activity of hypoxia-inducible factor-1alpha-prolyl-
hydroxylase 2 by a MYND-type zinc ﬁnger. Mol Pharmacol 2005;68:
1803–9.
Cancer Res; 79(16) August 15, 2019 Cancer Research4056
Kozlova et al.
on October 25, 2019. © 2019 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Published OnlineFirst May 29, 2019; DOI: 10.1158/0008-5472.CAN-18-3852 
2019;79:4042-4056. Published OnlineFirst May 29, 2019.Cancer Res 
  
Nina Kozlova, Daniela Mennerich, Anatoly Samoylenko, et al. 
  
Partner of Hypoxia-Inducible Factor Prolyl Hydroxylase 2
The Pro-Oncogenic Adaptor CIN85 Acts as an Inhibitory Binding
  
Updated version
  
 10.1158/0008-5472.CAN-18-3852doi:
Access the most recent version of this article at:
  
Material
Supplementary
  
 http://cancerres.aacrjournals.org/content/suppl/2019/05/29/0008-5472.CAN-18-3852.DC1
Access the most recent supplemental material at:
  
  
  
Overview
Visual
  
 http://cancerres.aacrjournals.org/content/79/16/4042/F1.large.jpg
A diagrammatic summary of the major findings and biological implications:
  
  
  
Cited articles
  
 http://cancerres.aacrjournals.org/content/79/16/4042.full#ref-list-1
This article cites 50 articles, 23 of which you can access for free at:
  
  
  
E-mail alerts  related to this article or journal.Sign up to receive free email-alerts
  
Subscriptions
Reprints and 
  
.pubs@aacr.org
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at
  
Permissions
  
Rightslink site. 
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
.http://cancerres.aacrjournals.org/content/79/16/4042
To request permission to re-use all or part of this article, use this link
on October 25, 2019. © 2019 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Published OnlineFirst May 29, 2019; DOI: 10.1158/0008-5472.CAN-18-3852 
